AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Genomic Cancer Panel and Profiling Market (2021 to 2025) - by Cancer, Application, Tissue and Gene Type - ResearchAndMarkets.com

July 5, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Jul 5, 2021--

The “Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with Screening potential Market Size, Forecasting/Analysis, and Executive and Consultant Guides 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding as physicians use all the information they can get in the battle against cancer. While Pharmaceutical Companies see the potential to make nearly any therapy viable. The report has data on how test volumes have grown for the biggest players. Find out how this new way of understanding cancer will change cancer diagnostics forever.

ADVERTISEMENT

Comprehensive panels, genomic profiling, high risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2021 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Forecast demand for new testing regimes or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.

Companies Mentioned

ADVERTISEMENT

  • 10x Genomics, Inc
  • Abbott Diagnostics
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent/Dako
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc
  • BioFluidica
  • BioGenex
  • BioIVT
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Burning Rock
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • And Many More Companies!

Key Topics Covered:

1 Market Guides

2 Introduction and Market Definition

3 Market Overview

4 Market Trends

5 Cancer Panels & Profiles Recent Developments

5.1 Recent Developments - Importance and How to Use This Section

5.2 Dante Labs Acquires Cambridge Cancer Genomics

5.3 Celemics, Strand Partner on Integrated Platform for NGS Analysis

5.4 Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries

5.5 Burning Rock Revenues Rise

5.6 Caris Life Sciences to Expand Liquid Biopsy Testing

5.7 OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence

5.8 Intermountain and Myriad Combine Test Offering

5.9 Illumina, Geneseeq to Offer Cancer Testing Kits in China

5.10 Exact Sciences to Offer End-to-End Cancer Testing

5.11 Guardant Health Turns to Tumor Tissue Sequencing

5.12 Tempus Inks Oncology Testing Collaboration With Bayer

5.13 Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform

5.14 Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test

5.15 Metastatic Cancer Markers Identified in Clinical WGS Study

5.16 Stitch Bio Bets on CRISPR Tech

5.17 Bayer, LifeLabs Launch Free NTRK Genetic Testing Program

5.18 Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx

5.19 Progress, Challenges in Liquid Biopsy Reimbursement

5.20 Israeli Startup Curesponse Raises $6M

5.21 Invitae, ArcherDX Merge to Advance Precision Oncology Offerings

5.22 MD Anderson Precision Oncology Decision Support to Use Philips’ Informatics Solution

5.23 NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program

5.24 Germline Results Guides Precision Therapy in Advanced Cancer

5.25 FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics

5.26 ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers

5.27 Labs Reporting Cancer Risk Mutations from Tumor Testing

5.28 Users Begin Integrating Genomics Data for Clinical Decision Support

5.29 Fujitsu Improves Efficiency in Cancer Genomic Medicine

5.30 Thermo Fisher’s automated sequencer to offer same-day, pan-cancer test results

5.31 Universal Genetic Testing for All Breast Cancer Patients

5.32 Exact Sciences buys Genomic Health

5.33 Multi-Gene Liquid Biopsy Breast Cancer Panel

5.34 Thrive to Develop Earlier Detection of Multiple Cancer Types

5.35 New Gene Panel Identifies High Risk Prostate Cancer

5.36 Guardant Health Liquid Biopsy Test to be Covered by EviCore

5.37 Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services

5.38 Natera Commercializes Tumor Whole Exome Sequencing from Plasma

5.39 Inivata Completes £39.8M Series B Funding Round

5.40 Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance

5.41 CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials

5.42 Biodesix Acquires Integrated Diagnostics

5.43 Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx

6 Profiles of Key Players

7 The Global Market for Cancer Gene Panels and Profiles

8 Global Cancer Gene Panels & Profiles Markets - By Type of Cancer

9 Global Cancer Gene Panels & Profiles Markets - By Type of Application

10 Global Cancer Gene Panels & Profiles Markets - By Tissue Type

11 Global Cancer Gene Testing Markets - Germline and Somatic

12 Potential Market Opportunity Sizes

13 Appendices

For more information about this report visit https://www.researchandmarkets.com/r/e6c1tk

View source version on businesswire.com:https://www.businesswire.com/news/home/20210705005161/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY MEDICAL DEVICES

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 07/05/2021 08:58 AM/DISC: 07/05/2021 08:58 AM

http://www.businesswire.com/news/home/20210705005161/en